Ramesh R, Aggarwal V, Choudhary A, Basu D, Nair N, Ganesan P
Asian Pac J Cancer Prev. 2024; 25(9):3229-3237.
PMID: 39342602
PMC: 11700331.
DOI: 10.31557/APJCP.2024.25.9.3229.
Gokbuget N, Ihrig K, Stadler M, Stelljes M, Elmaagacli A, Starck M
Haematologica. 2023; 108(7):1758-1767.
PMID: 36779593
PMC: 10316257.
DOI: 10.3324/haematol.2022.281820.
Abbas M, Bin Naeem S, Jhatial M, Bokhari S, Ahsan B, Ahmad U
Cureus. 2023; 14(12):e32936.
PMID: 36712765
PMC: 9873483.
DOI: 10.7759/cureus.32936.
Wirth A, Wange L, Vosberg S, Henrich K, Rausch C, Ozdemir E
Leukemia. 2022; 36(12):2863-2874.
PMID: 36333584
PMC: 9712105.
DOI: 10.1038/s41375-022-01726-7.
Sun G, Tang B, Song K, Wu Y, Tu M, Wan X
Stem Cell Res Ther. 2022; 13(1):500.
PMID: 36210439
PMC: 9549614.
DOI: 10.1186/s13287-022-03186-3.
Outcomes of patients with Down syndrome and acute leukemia: A retrospective observational study.
Schmidt M, Colita A, Ivanov A, Coriu D, Miron I
Medicine (Baltimore). 2021; 100(40):e27459.
PMID: 34622870
PMC: 8500660.
DOI: 10.1097/MD.0000000000027459.
Newly proposed threshold and validation of white blood cell count at diagnosis for Philadelphia chromosome-positive acute lymphoblastic leukemia: risk assessment of relapse in patients with negative minimal residual disease at transplantation-a....
Akahoshi Y, Arai Y, Nishiwaki S, Tachibana T, Shinohara A, Doki N
Bone Marrow Transplant. 2021; 56(11):2842-2848.
PMID: 34331021
DOI: 10.1038/s41409-021-01422-7.
Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.
Sasaki K, Kantarjian H, Morita K, Short N, Konopleva M, Jain N
Cancer. 2021; 127(18):3381-3389.
PMID: 34138471
PMC: 11849228.
DOI: 10.1002/cncr.33655.
Cryostorage to What End? - Autologous Stem Cell Products in Burkitt Lymphoma, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Myeloproliferative Neoplasm Patients.
Kriegsmann K, Pavel P, Bochtler T, Schmitt A, Sauer S, Kriegsmann M
Transfus Med Hemother. 2021; 48(2):91-98.
PMID: 33976609
PMC: 8077354.
DOI: 10.1159/000509945.
Prognostic Value of the Immunological Subtypes of Adolescent and Adult T-Cell Lymphoblastic Lymphoma; an Ultra-High-Risk Pro-T/CD2(-) Subtype.
Ostrowska B, Rymkiewicz G, Chechlinska M, Blachnio K, Domanska-Czyz K, Bystydzienski Z
Cancers (Basel). 2021; 13(8).
PMID: 33921074
PMC: 8071379.
DOI: 10.3390/cancers13081911.
Cytomegalovirus reactivation during adult acute lymphoblastic leukemia maintenance: do we underestimate (un)expected guest of pediatric approach?.
Ozbalak M, Guzel Mastanzade M, Gurel E, Kalayoglu Besisik S
Am J Blood Res. 2021; 11(1):118-122.
PMID: 33796399
PMC: 8010603.
CD1a is rarely expressed in pediatric or adult relapsed/refractory T-ALL: implications for immunotherapy.
Leong S, Inglott S, Papaleonidopoulou F, Orfinada K, Ancliff P, Bartram J
Blood Adv. 2020; 4(19):4665-4668.
PMID: 33002130
PMC: 7556151.
DOI: 10.1182/bloodadvances.2020002502.
Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.
Salhotra A, Yang D, Mokhtari S, Al Malki M, Ali H, Sandhu K
Biol Blood Marrow Transplant. 2020; 26(6):1084-1090.
PMID: 32035275
PMC: 9129096.
DOI: 10.1016/j.bbmt.2020.01.029.
Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance.
Herrmann A, Muller M, Orth M, Muller J, Zernecke A, Hochhaus A
J Cell Mol Med. 2020; 24(5):2942-2955.
PMID: 31957290
PMC: 7077607.
DOI: 10.1111/jcmm.14910.
Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatment.
Marks D, Oostrum I, Mueller S, Welch V, Vandendries E, Loberiza F
Cancer Med. 2019; 8(13):5959-5968.
PMID: 31436395
PMC: 6792500.
DOI: 10.1002/cam4.2480.
A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia.
Bassan R, Bruggemann M, Radcliffe H, Hartfield E, Kreuzbauer G, Wetten S
Haematologica. 2019; 104(10):2028-2039.
PMID: 30890593
PMC: 6886415.
DOI: 10.3324/haematol.2018.201053.
An observational study of Chinese adults with relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia.
Ma J, Liu T, Jin J, Hu J, Liu Q, Wang J
Int J Hematol Oncol. 2018; 7(2):IJH06.
PMID: 30405901
PMC: 6219430.
DOI: 10.2217/ijh-2018-0006.
Acute Lymphoblastic Leukemia in Young Adults Treated with Intensive "Pediatric" Type Protocol.
Ganesan P, Sagar T, Kannan K, Radhakrishnan V, Dhanushkodi M, Swaminathan R
Indian J Hematol Blood Transfus. 2018; 34(3):422-429.
PMID: 30127548
PMC: 6081315.
DOI: 10.1007/s12288-017-0892-y.
High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: a phase III study by JALSG.
Sakura T, Hayakawa F, Sugiura I, Murayama T, Imai K, Usui N
Leukemia. 2017; 32(3):626-632.
PMID: 28914260
DOI: 10.1038/leu.2017.283.
Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia.
Koprivnikar J, McCloskey J, Faderl S
Onco Targets Ther. 2017; 10:1413-1422.
PMID: 28331334
PMC: 5348069.
DOI: 10.2147/OTT.S106810.
